Think Big.

We deliver

The Galapagos group CSR report

20 years ago Onno van de Stolpe founded Galapagos together with two scientists

Galapagos R&D doubled in staff from 298 in December 2014 to 571 employees in December 2018

In 2015 we conducted 8 clinical studies, in 2019 we plan to conduct more than 40, an increase of 400%

Our cash balance increased from 198.4 million euro at years’ end 2014 to 1.291 billion euro in December 2018

From 68,751 average daily trading volume of ordinary shares on Euronext in 2014 to approximately 481,000 ordinary shares and ADS average daily trading volume on Euronext and Nasdaq year to date in 2019

Our ambition is to deliver 6 new targets, 3 preclinical candidates and 3 proof-of-concepts a year, and 1 Phase 3 start every other year

To date, 12 Galapagos compounds with novel modes of action discovered by us have entered studies in patients

We went from 8 investment banks covering Galapagos in 2008 to 19 in 2019

To date, we have 3 novel mechanisms showing promising patient results: filgotinib in multiple inflammatory diseases GLGP1690 in IPF and MOR106 in atopic dermatitis

In our senior management levels, 33% of our staff is female

On 20 June 2019 we will celebrate our 20th birthday as a company

In 2018, we nominated 4 new preclinical candidates, all with a novel mechanism of action

Our global presence extended from 4 sites in 2014 to 7 in 2018

In 2019, we plan to file our first medicine for registration

We went from 21 nationalities in 2015 to 38 in 2018

The stock price on Euronext has increased >1,000% and the market capitalization has increased from ~€62 million to ~€4.8 billion (>7,000%) from 10 May 2005 to 13 March 2019

We keep delivering.